Answer
It is unknown whether glucarpidase or its metabolites pass into human milk, and infant risk cannot be excluded; a decision to discontinue breastfeeding or discontinue/abstain from glucarpidase therapy must balance breastfeeding benefits for the child against treatment benefits for the woman.
Sources for this answer
- VoraxazeSERB · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 1Document updated
Sources checked